SPN-821 2400 mg
821P203
Phase 2 small_molecule active
Quick answer
SPN-821 2400 mg for Major Depressive Disorder (MDD) is a Phase 2 program (small_molecule) at SUPERNUS PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SUPERNUS PHARMACEUTICALS, INC.
- Indication
- Major Depressive Disorder (MDD)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active